1 day ago · Dupilumab (Dupixent), a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, is currently approved in the United States for a range of dermatologic and allergy …

3 days ago · DUPIXENT can cause allergic reactions that can sometimes be severe. ... Product Candidates and new indications for Regeneron’s Products, such as Dupixent for the treatment …

3 days ago · About DupixentDupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of …

This retrospective cohort study assesses the patient outcomes and safety of dupilumab in adults with bullous pemphigoid.

Apr 26, 2023 · This retrospective study from 3 academic institutions evaluates the outcomes of 17 patients diagnosed with BP, with reported biopsy with hematoxylin and eosin stain, biopsy with …

Oct 17, 2024 · Bullous pemphigoid (BP) is an autoimmune skin disease that affects elderly people. BP causes large, fluid-filled blisters on the skin and can be very itchy and …

Dupilumab seems to be an effective and safe option to treat recalcitrant BP. Here, we report the results of a literature review on the use of dupilumab in BP, including a total of 30 treated …

Feb 18, 2006 · Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid. If approved, Dupixent would be the first and only targeted medicine to …

Sep 11, 2024 · A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with …

Sep 11, 2005 · A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with …